ClinicalTrials.gg
CompletedNCT00112034Updated May 9, 2008

AVONEX® Combination Trial - "ACT"

A Phase 4 interventional study of Methotrexate and IV methylprednisolone in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2008-05-09.

Sponsored by Biogen · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Biogen.

Enrollment
17th of 59
350 · median 152
Started
2003
with 4 others
Phase 4
21 of 78
none open now
Registered
4th of 78
by date

Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 17th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2003, is one of 21 in phase 4, and was the 4th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Multiple Sclerosis
  • Relapsing-Remitting
  • AVONEX
  • Combination
  • Methotrexate
  • IV Methylprednisolone
  • IVMP
  • ACT
  • MTX
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 55, inclusive
  • Diagnosis of MS
  • A relapsing-remitting course
  • Expanded Disability Status Scale (EDSS) score 0.0-5.5 inclusive at Baseline
  • Currently receiving AVONEX® therapy
  • Treated with AVONEX® for at least 6 consecutive months prior
  • Breakthrough disease (clinical relapse or gadolinium-enhancing MRI lesion) during the prior 12 months, at least 6 months after initiating AVONEX therapy.

Exclusion criteria

Exclusion Criteria:

  • History of cirrhosis, chronic hepatitis, or currently active hepatitis
  • History of poorly-controlled hypertension, diabetes mellitus, or peptic ulcer disease
  • History of aseptic bone necrosis, osteoporosis, or osteoporosis-related bone fracture
  • History of -induced psychosis.
  • History of or abnormal laboratory results indicating significant illness
  • History of severe allergic or anaphylactic reactions or known drug or intolerance to MTX, IVMP, or AVONEX®.
  • History of allergy to albumin
  • History of any episode of suicidal ideation or severe depression within 3 months of the Screening Visit.
  • History of seizure within 3 months prior to the Screening Visit.
  • Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
  • MS relapse with onset within 60 days prior to the Baseline Visit
  • Any metallic or electronic material or device in the body, or condition that precludes the subject from undergoing MRI with gadolinium administration
  • A infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days of the Screening Visit
  • Abnormal blood tests, performed at the Screening Visit, which exceed any of the limits defined by the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double
Enrollment
350 participants
06

What researchers measure

Primary outcomes

  1. Brain MRI lesion activity measured by the combined number of T2-hyperintense lesions at Month 12 that are new or enlarged since Baseline

  2. effectiveness of AVONEX® and IVMP plus MTX in trying to reduce lesion activity on brain MRI

Secondary outcomes

  1. Gadolinium enhancing lesion number on brain MRI, relapse rate, MS Functional Composite change, whole brain atrophy progression

07

Study locations

1 site
  • MS Academic Coordinating Center
    Cleveland, Ohio 44195, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003, a primary completion of Jun 2006 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2005
First posted
May 30, 2005
Start
Jun 2003
Primary completionActual
Jun 2006
CompletionActual
May 2007
Last update
May 9, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00112034
Lead sponsor
Biogen
First posted
May 30, 2005
Start date
Jun 2003
Primary completion
Jun 2006
Completion
May 2007
Last update
May 9, 2008

Study contacts

Jeffrey A. Cohen, MD
principal investigator · The Cleveland Clinic
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Methylprednisolone

Start the discussion